PHAXIAM Therapeutics S.A.
PHXMNASDAQHealthcare
$3.10
$-0.17(-5.20%)
Market Cap$19855280
P/E Ratio—
52W High$13.0
52W Low$2.5
PHAXIAM Therapeutics S.A. (PHXM) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PHXM · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2022Report Date: Dec 31, 2022EPS Actual
$0.19
Revenue
—
Fiscal Period
Q4 FY2022
FY ends December
Report Date
Dec 31, 2022
After Market Close
PHXM reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $6.21B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$6.21B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q1 FY2024 | Mar 26, 2024 | — | — | — | — | — | — |
| ◌ Q3 FY2023 | Sep 21, 2023 | — | — | — | — | — | — |
| — Q4 FY2022 | Dec 31, 2022 | — | $0.19 | — | — | — | — |
| — Q3 FY2022 | Sep 30, 2022 | — | -$0.17 | — | — | — | — |
| — Q2 FY2022 | Jun 30, 2022 | — | $0.35 | — | — | — | — |
| — Q1 FY2022 | Mar 31, 2022 | — | -$0.38 | — | — | — | — |
| — Q4 FY2021 | Dec 31, 2021 | — | -$0.39 | — | — | — | — |
| — Q3 FY2021 | Sep 30, 2021 | — | -$0.49 | — | — | — | — |
Q1 FY2024
Mar 26, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2023
Sep 21, 2023
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2022
Dec 31, 2022
EPS Actual
$0.19
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2022
Sep 30, 2022
EPS Actual
-$0.17
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2022
Jun 30, 2022
EPS Actual
$0.35
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2022
Mar 31, 2022
EPS Actual
-$0.38
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2021
Dec 31, 2021
EPS Actual
-$0.39
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2021
Sep 30, 2021
EPS Actual
-$0.49
EPS Est.
—
EPS Surpr.
—
Revenue
—
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2024 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2023 | $0.00 | $0.00 | $0.00 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q4 FY2022 | Dec 31, 2022 | — | $3.30 | $3.41 | +3.33% |
| — Q3 FY2022 | Sep 30, 2022 | — | $5.40 | $5.50 | +1.85% |
| — Q2 FY2022 | Jun 30, 2022 | — | $11.20 | $11.20 | +0.00% |
| — Q1 FY2022 | Mar 31, 2022 | — | $17.80 | $17.50 | -1.69% |
| — Q4 FY2021 | Dec 31, 2021 | — | $23.60 | $23.50 | -0.42% |
| — Q3 FY2021 | Sep 30, 2021 | — | $58.30 | $57.70 | -1.03% |
| — Q2 FY2021 | Jun 30, 2021 | — | $48.27 | $48.30 | +0.06% |
| — Q1 FY2021 | Mar 31, 2021 | — | $70.70 | $70.41 | -0.41% |
Q4 FY2022+3.33%
Report Date
Dec 31, 2022
EPS Beat/Miss
—
Price Before
$3.30
Price After
$3.41
Q3 FY2022+1.85%
Report Date
Sep 30, 2022
EPS Beat/Miss
—
Price Before
$5.40
Price After
$5.50
Q2 FY2022+0.00%
Report Date
Jun 30, 2022
EPS Beat/Miss
—
Price Before
$11.20
Price After
$11.20
Q1 FY2022-1.69%
Report Date
Mar 31, 2022
EPS Beat/Miss
—
Price Before
$17.80
Price After
$17.50
Q4 FY2021-0.42%
Report Date
Dec 31, 2021
EPS Beat/Miss
—
Price Before
$23.60
Price After
$23.50
Q3 FY2021-1.03%
Report Date
Sep 30, 2021
EPS Beat/Miss
—
Price Before
$58.30
Price After
$57.70
Q2 FY2021+0.06%
Report Date
Jun 30, 2021
EPS Beat/Miss
—
Price Before
$48.27
Price After
$48.30
Q1 FY2021-0.41%
Report Date
Mar 31, 2021
EPS Beat/Miss
—
Price Before
$70.70
Price After
$70.41
Beat Rate0 / 8 quarters
Largest Move+3.33% (Q4 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PHXM ends December
PHAXIAM Therapeutics S.A. (PHXM) most recently reported earnings on December 31, 2022 for Q4 FY2022, posting EPS of $0.19 (in line with the analyst consensus of —). The next PHXM earnings date is expected around September 1, 2026.
Each quarter, investors track PHXM earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PHXM revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PHXM's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PHXM earnings · 4 questionsPHAXIAM Therapeutics S.A.'s next earnings report is expected around September 1, 2026. PHXM typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PHXM historically reports after market close (AMC).
PHXM earnings datewhen is PHXM earningsPHXM next earnings datewhen does PHXM report earningsPHXM earnings calendar
▸ Source: FMP · PHAXIAM Therapeutics S.A. SEC filings · US GAAP · PHAXIAM Therapeutics S.A. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026